Molecular characterisation of ERG, ETV1 and PTEN gene loci identifies patients at low and high risk of death from prostate cancer

@article{Reid2010MolecularCO,
  title={Molecular characterisation of ERG, ETV1 and PTEN gene loci identifies patients at low and high risk of death from prostate cancer},
  author={Alison H M Reid and G Attard and Laurence Ambroisine and Gabrielle Fisher and Gyoergy Kov{\'a}cs and Daniel S. Brewer and J P Clark and Penny Flohr and S Edwards and Daniel M. Berney and Christopher S Foster and Anne Fletcher and William L. Gerald and Henrik M{\o}ller and Victor E. Reuter and Peter T. Scardino and Jack M Cuzick and Johann S. de Bono and C. S. Cooper},
  journal={British Journal of Cancer},
  year={2010},
  volume={102},
  pages={678 - 684}
}
Background:The discovery of ERG/ETV1 gene rearrangements and PTEN gene loss warrants investigation in a mechanism-based prognostic classification of prostate cancer (PCa). The study objective was to evaluate the potential clinical significance and natural history of different disease categories by combining ERG/ETV1 gene rearrangements and PTEN gene loss status.Methods:We utilised fluorescence in situ hybridisation (FISH) assays to detect PTEN gene loss and ERG/ETV1 gene rearrangements in 308… Expand
Reconstitution of the ERG Gene Expression Network Reveals New Biomarkers and Therapeutic Targets in ERG Positive Prostate Tumors
TLDR
Three major signaling pathways related to MAPK/PI3K cascade that may indeed contribute synergistically to the ERG dependent tumor development are identified and have potential as biomarkers and therapeutic target for ERG positive prostate tumors. Expand
Clinical utility of assessing PTEN and ERG protein expression in prostate cancer patients: a proposed method for risk stratification
TLDR
A significant prognostic role for assessing ERG and PTEN in men with prostate cancer is confirmed and supports a role for utilizing combined ERG/PTEN status clinically and prospectively for stratifying PCa patients into different prognostic groups. Expand
Combination of Multiple Markers Predicts Prostate Cancer Outcome
TLDR
There was a significant association between the combined ERG- and EZH2 expression and PTEN deletion with PCa specific death and the results shows the great potential in using multiple biomarkers to predict PCa outcome. Expand
PTEN Loss as Determined by Clinical-grade Immunohistochemistry Assay Is Associated with Worse Recurrence-free Survival in Prostate Cancer.
TLDR
It is found that loss of the PTEN tumor suppressor gene in prostate tumors as assessed by tissue staining is correlated with shorter time to prostate cancer recurrence after radical prostatectomy and that there is no statistically significant interaction between PTEN and ERG status for RFS. Expand
Detection of ERG gene rearrangements and PTEN deletions in unsuspected prostate cancer of the transition zone
TLDR
Although TZ and peripheral zone tumors share similar molecular etiologies, they exhibit differences in the rates of ERG and PTEN aberrations, which may point toward a subset of tumors with adverse behavior. Expand
Loss of PTEN Is Associated with Aggressive Behavior in ERG-Positive Prostate Cancer
TLDR
A similar frequency of ERG positivity from early to late stage of the disease suggests lack of selection of ERg expression during disease progression, and the finding of consistent genetic alterations in different metastases suggests that the major genetic alterations take place in the primary tumor. Expand
Assessing the order of critical alterations in prostate cancer development and progression by IHC: further evidence that PTEN loss occurs subsequent to ERG gene fusion
TLDR
The combination of ERG and PTEN IHC staining can be used as a simple test to ascertain PTEN and ERG gene rearrangement status within a given prostate cancer in either a research or clinical setting. Expand
Decreased ATM Protein Expression Is Substantiated with PTEN Loss in Defining Aggressive Phenotype of Prostate Cancer Associated with Lethal Disease
TLDR
Understanding of how outcomes of patients with altered ATM and PTEN expression can be improved further with poly-ADP ribose polymerase inhibitors (PARPi), combinations of PARPi and androgen receptor–targeted therapies, as well as platinum-based chemotherapies is enhanced. Expand
Relative 8q gain predicts disease‐specific survival irrespective of the TMPRSS2‐ERG fusion status in diagnostic biopsies of prostate cancer
TLDR
It is concluded that relative 8q gain in diagnostic needle biopsies is a poor prognostic factor independent of the TMPRSS2‐ERG fusion gene status and of standard clinicopathological parameters. Expand
A Prospective Investigation of PTEN Loss and ERG Expression in Lethal Prostate Cancer.
TLDR
PTEN loss is independently associated with increased risk of lethal progression, particularly in the ERG fusion-negative subgroup, and these validated and inexpensive IHC assays may be useful for risk stratification in prostate cancer. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 39 REFERENCES
Absence of TMPRSS2:ERG fusions and PTEN losses in prostate cancer is associated with a favorable outcome
TLDR
A retrospective analysis of 125 prostate cancers with known clinical outcome using interphase fluorescence in situ hybridization and multivariate analysis indicate that TMPRSS2:ERG fusion and PTEN loss together are a predictor of earlier biochemical recurrence of disease. Expand
Association of TMPRSS2-ERG gene fusion with clinical characteristics and outcomes: results from a population-based study of prostate cancer
TLDR
If replicated, the results presented here may provide insight into the mechanism by which the TMPRSS2-ERG gene fusion arises and also contribute to diagnostic evaluations for determining the subset of men who will go on to develop metastatic prostate cancer. Expand
TMPRSS2-ERG gene fusion is not associated with outcome in patients treated by prostatectomy.
TLDR
It is concluded that translocation of TMPRSS2-ERG is not associated with outcome, and the aggressive clinical features associated with CNI of chromosome 21 reflect generalized aneuploidy and are not due to CNI specifically of rearranged TMPR SS1-ERG. Expand
Duplication of the fusion of TMPRSS2 to ERG sequences identifies fatal human prostate cancer
TLDR
It is concluded that determination of ERG gene status, including duplication of the fusion of TMPRSS2 to ERG sequences in 2+Edel, allows stratification of prostate cancer into distinct survival categories. Expand
ETS gene fusions in prostate cancer
Chromosomal rearrangements that result in high level expression of ETS gene family members are common events in human prostate cancer. Most frequently, the androgen-activated gene TMPRSS2 is foundExpand
Expression of the TMPRSS2:ERG fusion gene predicts cancer recurrence after surgery for localised prostate cancer
TLDR
Among prostate cancer patients treated with surgery, the expression of TMPRSS2:ERG fusion gene is a strong prognostic factor and is independent of grade, stage and PSA level. Expand
TMPRSS2:ERG gene fusion associated with lethal prostate cancer in a watchful waiting cohort
TLDR
A population-based cohort of men with localized prostate cancers followed by expectant (watchful waiting) therapy with 15% (17/111) TMPRSS2:ERG fusion is reported, finding a statistically significant association between TMPR SS2-ERG fusion and prostate cancer specific death. Expand
FISH analysis of 107 prostate cancers shows that PTEN genomic deletion is associated with poor clinical outcome
TLDR
PTEN loss at the time of prostatectomy correlated with clinical parameters of more advanced disease, such as extraprostatic extension and seminal vesicle invasion, and indicates that haploinsufficiency or PTEN genomic loss is an indicator of moreAdvanced disease at surgery, and is predictive of a shorter time to biochemical recurrence of disease. Expand
PTEN genomic deletion is associated with p‐Akt and AR signalling in poorer outcome, hormone refractory prostate cancer
PTEN haploinsufficiency is common in hormone‐sensitive prostate cancer, though the incidence of genomic deletion and its downstream effects have not been elucidated in clinical samples of hormoneExpand
Heterogeneity and clinical significance of ETV1 translocations in human prostate cancer
TLDR
In 5′-RACE experiments on RNA extracted from formalin-fixed tissue, the androgen-upregulated gene ACSL3 is identified as a new 5-translocation partner of ETV1 and these studies report a novel fusion partner for ETV2 and highlight the considerable heterogeneity of E TV1 gene rearrangements in human prostate cancer. Expand
...
1
2
3
4
...